Ann: Nyrada Commences Walter Reed Traumatic Brain Injury Study, page-176

  1. 914 Posts.
    lightbulb Created with Sketch. 437
    So, I'm heavily invested in NYR, have been for many years, but I still think this has a long way to fall.

    - The company has been close to a decade in preclinical and are yet to show any expertise in running clinical trials.
    - Their previous (lead) drug, treating high cholesterol failed due to toxic side effects
    - Still haven't secured patent IP protection for their asset
    - NYR has a long track record of missed and slipped timelines
    - NOX owns a large chunk of NYR, and NOX will start offloading at any positive price movements. This is a massive anchor around NYR neck.
    - They don't seem to have a plan B if the current TBI drug fails in Phase 1 (as 90%+ of drugs do).
    - The much-hoped for Walter Reed funding will be non-existent under a Trump presidency.



 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
29.0¢
Change
0.000(0.00%)
Mkt cap ! $61.32M
Open High Low Value Volume
29.0¢ 29.0¢ 28.0¢ $159.0K 561.3K

Buyers (Bids)

No. Vol. Price($)
3 25000 29.0¢
 

Sellers (Offers)

Price($) Vol. No.
29.5¢ 34962 2
View Market Depth
Last trade - 11.17am 07/08/2025 (20 minute delay) ?
NYR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.